CONCERT PHARMACEUTICALS INC (CNCE) Forecast, Price Target & Analyst Ratings

Name: CONCERT PHARMACEUTICALS INC (CNCE) Analyst Consensus Rating
Brand: CONCERT PHARMACEUTICALS INC
Rating: 8 (11 reviews)

NASDAQ:CNCE • US2060221056

8.37 USD

+0.01 (+0.12%)

At close: Mar 3, 2023

8.4 USD

+0.03 (+0.36%)

After Hours: 3/3/2023, 8:00:00 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CONCERT PHARMACEUTICALS INC (CNCE).

Consensus Price Target

Price Target

$11.90

+ 42.17% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: May 3, 2023
Period: Q4 / 2022
EPS Estimate: -$0.65
Revenue Estimate: 115.597K

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

78.18%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$11.90

Upside

+ 42.17%

From current price of $8.37 to mean target of $11.90, Based on 11 analyst forecasts

Low

$9.09

Median

$9.18

High

$17.85

Price Target Revisions

1 Month

0.00%

3 Months

-32.95%

Price Target Summary

11 Wall Street analysts provided a forecast for the next 12 months for CNCE. The average price target is 11.9 USD. This implies a price increase of 42.17% is expected in the next year compared to the current price of 8.37.

The average price target has been revised downward by 32.95% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

78.18%

CNCE was analyzed by 11 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CNCE.

In the previous month the buy percentage consensus was at a similar level.

CNCE was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2023-01-20	JonesTrading	Downgrade	Buy -> Hold
2022-09-13	Truist Securities	Maintains	Buy
2022-08-25	JonesTrading	Initiate	Buy
2021-10-05	Mizuho	Maintains	Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date: May 3, 2023
Period: Q4 / 2022
EPS Estimate: -$0.65
Revenue Estimate: 115.597K
Revenue Q2Q: 789.20%
EPS Q2Q: 35.87%
Number of Analysts: 6

Next Earnings Revisions

Revenue (1 Month)

33.33%

Revenue (3 Months)

33.33%

EPS (1 Month)

0.78%

EPS (3 Months)

0.78%

Next Earnings Summary

CNCE is expected to report earnings on 5/3/2023. The consensus EPS estimate for the next earnings is -0.65 USD and the consensus revenue estimate is 115.60K USD.

The next earnings revenue estimate has been revised upward by 33.33% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2022 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
Revenue YoY % growth	1.1M -89.52%	7.9M 618.18%	32.578M 312.38%	101.745K -99.69%	13.117M 12,792.03%	32.379M 146.85%	98.278M 203.52%	195.14M 98.56%	280.94M 43.97%	393.58M 40.09%	441.06M 12.06%	483.99M 9.73%
EBITDA YoY % growth	-77.3M -42.10%	-71M 8.15%	-76.029M -7.08%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT YoY % growth	-79M -42.09%	-72.6M 8.10%	-77.508M -6.76%	-123.736M -59.64%	-137.334M -10.99%	-129.491M 5.71%	-79.059M 38.95%	3.768M 104.77%	78.9M 1,993.95%	177.26M 124.66%	217.15M 22.50%	253.18M 16.59%
Operating Margin	-7,181.82%	-918.99%	-237.92%	-121,614.29%	-1,046.99%	-399.92%	-80.44%	1.93%	28.08%	45.04%	49.23%	52.31%
EPS YoY % growth	-3.29 -37.66%	-2.40 27.05%	-2.30 4.17%	-2.82 -22.75%	-2.80 0.94%	-2.11 24.51%	-0.84 60.39%	0.03 103.05%	0.71 2,680.00%	1.68 136.69%	1.85 10.33%	2.07 11.85%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q4 / 22	Q1 / 23	Q2 / 23	Q3 / 23	Q4 / 23
EPS Q2Q % growth	-0.65 35.87%	-0.83 19.79%	-0.71 -20.15%	-0.70 -21.34%	-0.66 -2.36%
Revenue Q2Q % growth	115.597K 789.20%		-100.00%	-100.00%	5.1M 4,311.89%
EBITDA Q2Q % growth	N/A	N/A	N/A	N/A	N/A
EBIT Q2Q % growth	-28.307M 14.10%	-38.76M -7.58%	-44.88M 27.28%	-48.96M -65.37%	-43.86M -54.94%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

2.66%

EPS Next 5 Year

15.00%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

-0.95%

Revenue Next 5 Year

42.40%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

N/A

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CONCERT PHARMACEUTICALS INC / CNCE Forecast FAQ

Can you provide the average price target for CONCERT PHARMACEUTICALS INC stock?

11 analysts have analysed CNCE and the average price target is 11.9 USD. This implies a price increase of 42.17% is expected in the next year compared to the current price of 8.37.

Can you provide the upcoming earnings date for CONCERT PHARMACEUTICALS INC?

CONCERT PHARMACEUTICALS INC (CNCE) will report earnings on 2023-05-03.

Can you provide the consensus estimates for CONCERT PHARMACEUTICALS INC next earnings?

The consensus EPS estimate for the next earnings of CONCERT PHARMACEUTICALS INC (CNCE) is -0.65 USD and the consensus revenue estimate is 115.60K USD.

How many analysts cover CONCERT PHARMACEUTICALS INC (CNCE) stock?

The number of analysts covering CONCERT PHARMACEUTICALS INC (CNCE) is 11.

Analyst forecast overview

Forecast Snapshot